The randomized, double-blind, placebo-controlled, Phase II study is being conducted at 20 centers throughout the US. The objective of this study is to examine the safety and efficacy of MM-093 in patients with moderate to severe, active rheumatoid arthritis despite treatment with stable doses of methotrexate.
William Slichenmyer, senior vice president and chief medical officer at Merrimack, said: “We believe MM-093 represents a promising and novel approach to the treatment of a broad range of autoimmune diseases. We look forward to completing the study and communicating the results later this year.”